spironolactone has been researched along with Acute Disease in 45 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
Acute Disease: Disease having a short and relatively severe course.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the efficacy of oral spironolactone in patients with acute central serous chorioretinopathy (CSC)." | 9.27 | Spironolactone versus observation in the treatment of acute central serous chorioretinopathy. ( Fang, W; Ge, W; Li, J; Liu, Q; Shuai, Y; Sun, X; Yuan, S, 2018) |
| "We evaluated 12-month cost utilization data from 1516 heart failure outpatients enrolled in the Quality-of-Life Substudy of the Eplerenone Post-Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS)." | 9.14 | Patient health status and costs in heart failure: insights from the eplerenone post-acute myocardial infarction heart failure efficacy and survival study (EPHESUS). ( Chan, PS; Jones, PG; Nallamothu, BK; Soto, G; Spertus, JA; Weintraub, WS; Zhang, Z, 2009) |
| "Differences in the clinical impacts of the aldosterone receptor antagonists spironolactone and eplerenone in patients with heart failure (HF) are unclear." | 7.91 | Comparison of effects of aldosterone receptor antagonists spironolactone and eplerenone on cardiovascular outcomes and safety in patients with acute decompensated heart failure. ( Aonuma, K; Baba, M; Hamada-Harimura, Y; Higuchi, H; Ishizu, T; Machino-Ohtsuka, T; Nakatsukasa, T; Nishi, I; Obara, K; Sai, S; Seo, Y; Sugano, A; Yamamoto, M, 2019) |
| "BACKGROUND In the setting of acute decompensated heart failure (ADHF), tolvaptan, a selective V₂ receptor antagonist, did not alter plasma renin activity or angiotensin II level, but significantly increased plasma aldosterone by the activation of V₁ₐ receptor, suggesting that a high-dose mineralocorticoid receptor antagonist (MRA) combined with a V₂ receptor antagonist might be of interest, especially in ADHF patients." | 7.91 | Adding High-Dose Spironolactone to Tolvaptan Improves Acute Decompensated Heart Failure Due to Obstructive Hypertrophic Cardiomyopathy and Aortic Stenosis: A Case Report. ( Kajimoto, K; Otsubo, S, 2019) |
| "We investigated the relationship between spironolactone use and all-cause mortality in acute decompensated heart failure (ADHF) patients with severe renal dysfunction." | 7.81 | Clinical benefit of spironolactone in patients with acute decompensated heart failure and severe renal dysfunction: Data from the Korean Heart Failure Registry. ( Chae, SC; Cho, MC; Choi, DJ; Han, S; Hong, N; Jeon, ES; Kang, SM; Kim, JJ; Lee, MM; Oh, BH; Oh, J; Ryu, KH; Song, MK; Yoo, BS; Youn, JC, 2015) |
| "In patients with severe left ventricular dysfunction (EF < 30%) after acute myocardial infarction long-term treatment with spironolactone at daily dose 25-50 mg does not reduce mortality rate in long-term follow-up." | 7.73 | [Effect of spironolactone on mortality in patients with severe left ventricular dysfunction after acute myocardial infarction]. ( Chizyński, K; Goch, JH; Maciejewski, M; Ptaszyński, P; Ruta, J, 2006) |
| " Mineralocorticoid receptor antagonists administered at high doses may relieve congestion, overcome diuretic resistance, and mitigate the effects of adverse neurohormonal activation in AHF." | 6.84 | Efficacy and Safety of Spironolactone in Acute Heart Failure: The ATHENA-HF Randomized Clinical Trial. ( Anstrom, KJ; Braunwald, E; Butler, J; Desvigne-Nickens, P; Felker, GM; Givertz, MM; Hernandez, AF; Kalogeropoulos, AP; Konstam, MA; Mann, DL; Margulies, KB; McNulty, SE; Mentz, RJ; Redfield, MM; Shah, M; Tang, WHW; Whellan, DJ, 2017) |
| "To evaluate the efficacy of oral spironolactone in patients with acute central serous chorioretinopathy (CSC)." | 5.27 | Spironolactone versus observation in the treatment of acute central serous chorioretinopathy. ( Fang, W; Ge, W; Li, J; Liu, Q; Shuai, Y; Sun, X; Yuan, S, 2018) |
| "We evaluated 12-month cost utilization data from 1516 heart failure outpatients enrolled in the Quality-of-Life Substudy of the Eplerenone Post-Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS)." | 5.14 | Patient health status and costs in heart failure: insights from the eplerenone post-acute myocardial infarction heart failure efficacy and survival study (EPHESUS). ( Chan, PS; Jones, PG; Nallamothu, BK; Soto, G; Spertus, JA; Weintraub, WS; Zhang, Z, 2009) |
| "Differences in the clinical impacts of the aldosterone receptor antagonists spironolactone and eplerenone in patients with heart failure (HF) are unclear." | 3.91 | Comparison of effects of aldosterone receptor antagonists spironolactone and eplerenone on cardiovascular outcomes and safety in patients with acute decompensated heart failure. ( Aonuma, K; Baba, M; Hamada-Harimura, Y; Higuchi, H; Ishizu, T; Machino-Ohtsuka, T; Nakatsukasa, T; Nishi, I; Obara, K; Sai, S; Seo, Y; Sugano, A; Yamamoto, M, 2019) |
| "BACKGROUND In the setting of acute decompensated heart failure (ADHF), tolvaptan, a selective V₂ receptor antagonist, did not alter plasma renin activity or angiotensin II level, but significantly increased plasma aldosterone by the activation of V₁ₐ receptor, suggesting that a high-dose mineralocorticoid receptor antagonist (MRA) combined with a V₂ receptor antagonist might be of interest, especially in ADHF patients." | 3.91 | Adding High-Dose Spironolactone to Tolvaptan Improves Acute Decompensated Heart Failure Due to Obstructive Hypertrophic Cardiomyopathy and Aortic Stenosis: A Case Report. ( Kajimoto, K; Otsubo, S, 2019) |
| "We investigated the relationship between spironolactone use and all-cause mortality in acute decompensated heart failure (ADHF) patients with severe renal dysfunction." | 3.81 | Clinical benefit of spironolactone in patients with acute decompensated heart failure and severe renal dysfunction: Data from the Korean Heart Failure Registry. ( Chae, SC; Cho, MC; Choi, DJ; Han, S; Hong, N; Jeon, ES; Kang, SM; Kim, JJ; Lee, MM; Oh, BH; Oh, J; Ryu, KH; Song, MK; Yoo, BS; Youn, JC, 2015) |
| "In patients with severe left ventricular dysfunction (EF < 30%) after acute myocardial infarction long-term treatment with spironolactone at daily dose 25-50 mg does not reduce mortality rate in long-term follow-up." | 3.73 | [Effect of spironolactone on mortality in patients with severe left ventricular dysfunction after acute myocardial infarction]. ( Chizyński, K; Goch, JH; Maciejewski, M; Ptaszyński, P; Ruta, J, 2006) |
| " Mineralocorticoid receptor antagonists administered at high doses may relieve congestion, overcome diuretic resistance, and mitigate the effects of adverse neurohormonal activation in AHF." | 2.84 | Efficacy and Safety of Spironolactone in Acute Heart Failure: The ATHENA-HF Randomized Clinical Trial. ( Anstrom, KJ; Braunwald, E; Butler, J; Desvigne-Nickens, P; Felker, GM; Givertz, MM; Hernandez, AF; Kalogeropoulos, AP; Konstam, MA; Mann, DL; Margulies, KB; McNulty, SE; Mentz, RJ; Redfield, MM; Shah, M; Tang, WHW; Whellan, DJ, 2017) |
| " The ATHENA-HF (Aldosterone Targeted Neurohormonal Combined with Natriuresis Therapy in Heart Failure) trial is a randomized, double-blind, placebo-controlled study of the safety and efficacy of 100 mg/day spironolactone versus placebo (or continued low-dose spironolactone use in participants who are already receiving spironolactone at baseline) in 360 patients hospitalized for AHF." | 2.82 | Rationale and Design of the ATHENA-HF Trial: Aldosterone Targeted Neurohormonal Combined With Natriuresis Therapy in Heart Failure. ( Anstrom, KJ; Braunwald, E; Butler, J; Felker, GM; Hernandez, AF; Kalogeropoulos, A; Konstam, MA; Redfield, MM; Shah, MR; Tang, WH, 2016) |
| "Hyperaldosteronism was confirmed in 74% of 72 consecutive patients admitted for acute myocardial infarction, in 85% if patients previously treated by an antialdosterone drug or admitted after the acute phase are excluded, and in 96% if patients with cardiac failure are included." | 2.65 | [Hyperaldosteronism in the acute phase of myocardial infarction. Effects of its treatment on the prevention of ventricular fibrillation]. ( Denis, B; Dimitriou, R; Machecourt, J; Page, E; Reboud, JP; Wolf, JE, 1984) |
| "furosemide dose or were switched furosemide to oral route (fast diuretic response, FDR)." | 1.39 | Tailoring diuretic therapy in acute heart failure: insight into early diuretic response predictors. ( Almeida, S; Bettencourt, P; Carvalho, H; Ferreira, JP; Marques, I; Santos, M, 2013) |
| "A case of systemic lupus erythematosus (SLE) associated with fever, heart failure, and left ventricular (LV) aneurysm is reported." | 1.29 | Acute myocarditis and left ventricular aneurysm as presentations of systemic lupus erythematosus. ( Caldarulo, M; Frustaci, A; Gentiloni, N, 1996) |
| " The regime used was spironolactone in a dosage of 25 mg three times a day for two days preceding and during the periods spent at altitudes above 3,000 m." | 1.26 | Spironolactone and acute mountain sickness. ( Carter, PH; Champion, WL; Currie, TT; Fong, G; Francis, JK; McDonald, IH; Newing, RK; Nunn, IN; Sisson, RN; Sussex, M; Zacharin, RF, 1976) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 17 (37.78) | 18.7374 |
| 1990's | 2 (4.44) | 18.2507 |
| 2000's | 8 (17.78) | 29.6817 |
| 2010's | 17 (37.78) | 24.3611 |
| 2020's | 1 (2.22) | 2.80 |
| Authors | Studies |
|---|---|
| Yokota, T | 1 |
| Koiwa, H | 1 |
| Matsushima, S | 1 |
| Tsujinaga, S | 1 |
| Naya, M | 1 |
| Morisaki, H | 1 |
| Morisaki, T | 1 |
| Yan, S | 1 |
| Yu, J | 1 |
| Xia, Z | 1 |
| Zhu, B | 1 |
| Hu, J | 1 |
| Li, J | 2 |
| Butler, J | 2 |
| Anstrom, KJ | 2 |
| Felker, GM | 2 |
| Givertz, MM | 1 |
| Kalogeropoulos, AP | 1 |
| Konstam, MA | 2 |
| Mann, DL | 1 |
| Margulies, KB | 1 |
| McNulty, SE | 1 |
| Mentz, RJ | 1 |
| Redfield, MM | 2 |
| Tang, WHW | 1 |
| Whellan, DJ | 1 |
| Shah, M | 1 |
| Desvigne-Nickens, P | 1 |
| Hernandez, AF | 2 |
| Braunwald, E | 2 |
| Sun, X | 1 |
| Shuai, Y | 1 |
| Fang, W | 1 |
| Ge, W | 1 |
| Yuan, S | 1 |
| Liu, Q | 1 |
| Yamamoto, M | 1 |
| Seo, Y | 1 |
| Ishizu, T | 1 |
| Nishi, I | 1 |
| Hamada-Harimura, Y | 1 |
| Machino-Ohtsuka, T | 1 |
| Higuchi, H | 1 |
| Sai, S | 1 |
| Nakatsukasa, T | 1 |
| Sugano, A | 1 |
| Baba, M | 1 |
| Obara, K | 1 |
| Aonuma, K | 1 |
| Kajimoto, K | 1 |
| Otsubo, S | 1 |
| Bansal, S | 2 |
| Munoz, K | 1 |
| Brune, S | 1 |
| Bailey, S | 1 |
| Prasad, A | 1 |
| Velagapudi, C | 1 |
| Ferreira, JP | 3 |
| Santos, M | 3 |
| Almeida, S | 2 |
| Marques, I | 3 |
| Bettencourt, P | 3 |
| Carvalho, H | 3 |
| Eng, M | 1 |
| Maier, M | 1 |
| Stumpfe, S | 1 |
| Feucht, N | 1 |
| Strobl, P | 1 |
| Rath, V | 1 |
| Lohmann, CP | 1 |
| Hundertmark, M | 1 |
| Frantz, S | 1 |
| Asakura, M | 1 |
| Yamamoto, H | 1 |
| Asai, K | 1 |
| Hanatani, A | 1 |
| Hirata, K | 1 |
| Hirayakma, A | 1 |
| Kimura, K | 1 |
| Kobayashi, Y | 1 |
| Momomura, S | 1 |
| Nakagawa, Y | 1 |
| Nishi, Y | 1 |
| Saito, Y | 1 |
| Satoh, Y | 1 |
| Yamada, T | 1 |
| Yamashina, A | 1 |
| Yasuda, S | 1 |
| Yoshikawa, T | 1 |
| Kada, A | 1 |
| Uesaka, H | 1 |
| Kitakaze, M | 1 |
| Oh, J | 1 |
| Kang, SM | 1 |
| Song, MK | 1 |
| Hong, N | 1 |
| Youn, JC | 1 |
| Han, S | 1 |
| Jeon, ES | 1 |
| Cho, MC | 1 |
| Kim, JJ | 1 |
| Yoo, BS | 1 |
| Chae, SC | 1 |
| Oh, BH | 1 |
| Choi, DJ | 1 |
| Lee, MM | 1 |
| Ryu, KH | 1 |
| Oliveira, JC | 1 |
| Kalogeropoulos, A | 1 |
| Tang, WH | 1 |
| Shah, MR | 1 |
| Chan, PS | 1 |
| Soto, G | 1 |
| Jones, PG | 1 |
| Nallamothu, BK | 1 |
| Zhang, Z | 1 |
| Weintraub, WS | 1 |
| Spertus, JA | 1 |
| Januzzi, JL | 1 |
| Rehman, S | 1 |
| Mueller, T | 1 |
| van Kimmenade, RR | 1 |
| Lloyd-Jones, DM | 1 |
| Dobre, D | 1 |
| Rossignol, P | 1 |
| Murin, J | 1 |
| Parkhomenko, A | 1 |
| Lamiral, Z | 1 |
| Krum, H | 1 |
| van Veldhuisen, DJ | 1 |
| Pitt, B | 2 |
| Zannad, F | 1 |
| Trifonov, IR | 1 |
| Blohm, ME | 1 |
| Schroten, H | 1 |
| Heusch, A | 1 |
| Christaras, A | 1 |
| Micek, M | 1 |
| Wintgens, J | 1 |
| Mayatepek, E | 1 |
| Hoehn, T | 1 |
| Klein, JD | 1 |
| Murrell, BP | 1 |
| Tucker, S | 1 |
| Kim, YH | 1 |
| Sands, JM | 1 |
| Ruta, J | 1 |
| Ptaszyński, P | 1 |
| Maciejewski, M | 1 |
| Chizyński, K | 1 |
| Goch, JH | 1 |
| Denis, B | 1 |
| Dimitriou, R | 1 |
| Machecourt, J | 1 |
| Wolf, JE | 1 |
| Page, E | 1 |
| Reboud, JP | 1 |
| Fukushima, Y | 1 |
| Lewy, JE | 1 |
| Frustaci, A | 1 |
| Gentiloni, N | 1 |
| Caldarulo, M | 1 |
| Corazza, M | 1 |
| Strumìa, R | 1 |
| Lombardi, AR | 1 |
| Virgili, A | 1 |
| Schnur, W | 1 |
| Stagnara, J | 1 |
| Balagny, E | 1 |
| Cossalter, B | 1 |
| Dommerges, JP | 1 |
| Dournel, C | 1 |
| Drahi, E | 1 |
| Gauchez, H | 1 |
| Guillot, F | 1 |
| Javault, D | 1 |
| Lagardère, B | 1 |
| Le Masne, A | 1 |
| Lesprit, E | 1 |
| Maidenberg, M | 1 |
| Maufroy, D | 1 |
| Picherot, G | 1 |
| Renaud, H | 1 |
| Robert, J | 1 |
| Undreiner, F | 1 |
| Ramsay, LE | 1 |
| Castagnolo, B | 1 |
| De Colibus, V | 1 |
| Napolitano, L | 1 |
| Aliperta, A | 1 |
| Caldarelli, G | 1 |
| Abignente, F | 1 |
| Drozdova, ES | 1 |
| Brookfield, DS | 1 |
| Liston, WA | 1 |
| Brown, GV | 1 |
| Svetek, F | 1 |
| Kropec, I | 1 |
| Mrduljas, M | 1 |
| Currie, TT | 2 |
| Carter, PH | 1 |
| Champion, WL | 1 |
| Fong, G | 1 |
| Francis, JK | 1 |
| McDonald, IH | 1 |
| Newing, RK | 1 |
| Nunn, IN | 1 |
| Sisson, RN | 1 |
| Sussex, M | 1 |
| Zacharin, RF | 1 |
| McFarlane, AC | 1 |
| Wathen, CG | 1 |
| MacDonald, T | 1 |
| Wise, LA | 1 |
| Boyd, SM | 1 |
| Larsen, RF | 1 |
| Rock, PB | 1 |
| Fulco, CS | 1 |
| Edelman, B | 1 |
| Young, AJ | 1 |
| Cymerman, A | 1 |
| Ilinich, VK | 1 |
| Plastun, FF | 1 |
| Rawlins, MD | 1 |
| Wildhirt, E | 1 |
| Schmidt, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Aldosterone Targeted Neurohormonal Combined With Natriuresis Therapy - HF (ATHENA-HF)[NCT02235077] | Phase 2 | 360 participants (Actual) | Interventional | 2014-12-30 | Completed | ||
| High-Dose Aldactone for Treatment of Diuretic Resistant Heart Failure[NCT02429388] | Phase 4 | 0 participants (Actual) | Interventional | 2014-05-31 | Withdrawn (stopped due to Principal Investigator left institution prior to subjects being enrolled) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Baseline body weight assessment will be completed, and changes in weight documented daily through 96 hours or earlier discharge (NCT02235077)
Timeframe: Randomization through 96 hours or earlier discharge
| Intervention | pounds (Mean) |
|---|---|
| Spironolactone | -8.1 |
| Placebo | -7.5 |
Clinical congestion score will be assessed at randomization, 96 hours, and at discharge. Scale consisted of sum of six signs and symptoms of congestion, each scored 0-3. Zero indicates no sign/symptom and 3 indicates worst case of sign/symptom. Score range 0-18 with 18 being worst score. (NCT02235077)
Timeframe: Randomization through 96 hours
| Intervention | units on a scale (Mean) |
|---|---|
| Spironolactone | -5.59 |
| Placebo | -5.82 |
Dyspnea visual analog scale change from randomization to 96 hours. Scale range 0-100 with 100 being the best possible score. (NCT02235077)
Timeframe: Randomization to 96 hours
| Intervention | units on a scale (Mean) |
|---|---|
| Spironolactone | 17.2 |
| Placebo | 17.9 |
The Core Laboratory at Vermont will determine NT-proBNP levels for calculation of the endpoint from samples obtained at randomization and 96 hours respectively. NT-proBNP was converted to log scale. (NCT02235077)
Timeframe: Randomization to 96 hours
| Intervention | log pg/ml (Mean) |
|---|---|
| Spironolactone | -0.58 |
| Placebo | -0.61 |
Renal function via serum creatinine, will be assessed at randomization and daily through 96 hours (NCT02235077)
Timeframe: Randomization through 96 hours
| Intervention | mg/dl (Mean) |
|---|---|
| Spironolactone | 0.15 |
| Placebo | 0.16 |
Change in serum potassium levels at 96 hours as compared to baseline. (NCT02235077)
Timeframe: Baseline, 96 hours
| Intervention | mEq/L (Mean) |
|---|---|
| Spironolactone | 0.31 |
| Placebo | 0.15 |
Fluid intake and urine output will be assessed daily while in hospital through 96 hours. Net fluid output (output minus input) through 96 hours is reported. (NCT02235077)
Timeframe: Randomization through 96 hours
| Intervention | ml (Mean) |
|---|---|
| Spironolactone | 5824 |
| Placebo | 5507 |
Medications will be reviewed to assess loop diuretic dose requirements through Day 30 following randomization (NCT02235077)
Timeframe: Randomization through Day 30
| Intervention | mg (Mean) |
|---|---|
| Spironolactone | 19.66 |
| Placebo | 30.70 |
All participants will be contacted by telephone at 60 days, +/- 3 days post randomization to assess vital status (death). (NCT02235077)
Timeframe: 60 days post randomization
| Intervention | Participants (Count of Participants) |
|---|---|
| Spironolactone | 8 |
| Placebo | 10 |
Outpatient worsening heart failure symptoms will be assessed from discharge through Day 30 (NCT02235077)
Timeframe: Hospital discharge through Day 30
| Intervention | Participants (Count of Participants) |
|---|---|
| Spironolactone | 19 |
| Placebo | 17 |
4 reviews available for spironolactone and Acute Disease
| Article | Year |
|---|---|
[Heart failure: new insights and developments].
Topics: Acute Disease; Aminobutyrates; Biphenyl Compounds; Cardiac Resynchronization Therapy; Combined Modal | 2014 |
Diuretics in infancy.
Topics: Acute Disease; Benzothiadiazines; Diet, Sodium-Restricted; Diuretics; Diuretics, Osmotic; Edema; Eth | 1981 |
[Treatment of acute hepatic insufficiency (a survey of the literature)].
Topics: Acute Disease; Adenosine Triphosphate; Arginine; Chemical and Drug Induced Liver Injury; Exchange Tr | 1972 |
Variability in response to drugs.
Topics: Acute Disease; Acylation; Chlorthalidone; Chronic Disease; Depression; Diazoxide; Digoxin; Dose-Resp | 1974 |
14 trials available for spironolactone and Acute Disease
| Article | Year |
|---|---|
Efficacy and Safety of Spironolactone in Acute Heart Failure: The ATHENA-HF Randomized Clinical Trial.
Topics: Acute Disease; Aged; Dose-Response Relationship, Drug; Double-Blind Method; Female; Heart Failure; H | 2017 |
Spironolactone versus observation in the treatment of acute central serous chorioretinopathy.
Topics: Acute Disease; Administration, Oral; Adult; Central Serous Chorioretinopathy; Female; Fluorescein An | 2018 |
High-Dose Spironolactone When Patients With Acute Decompensated Heart Failure Are Resistant to Loop Diuretics: A Pilot Study.
Topics: Acute Disease; Aged; Diuretics; Drug Resistance; Female; Heart Failure; Humans; Male; Middle Aged; P | 2019 |
Mineralocorticoid receptor antagonism in acutely decompensated chronic heart failure.
Topics: Acute Disease; Aged; Aged, 80 and over; Chronic Disease; Disease Progression; Diuretics; Edema; Fema | 2014 |
Rationale and Design of the Double-Blind, Randomized, Placebo-Controlled Multicenter Trial on Efficacy of Early Initiation of Eplerenone Treatment in Patients with Acute Heart Failure (EARLIER).
Topics: Acute Disease; Adult; Clinical Protocols; Double-Blind Method; Early Medical Intervention; Eplerenon | 2015 |
Influence of spironolactone on matrix metalloproteinase-2 in acute decompensated heart failure.
Topics: Acute Disease; Aged; Aged, 80 and over; Body Weight; Creatinine; Diuretics; Female; Heart Failure; H | 2015 |
Rationale and Design of the ATHENA-HF Trial: Aldosterone Targeted Neurohormonal Combined With Natriuresis Therapy in Heart Failure.
Topics: Acute Disease; Cause of Death; Disease Progression; Double-Blind Method; Dyspnea; Heart Failure; Hum | 2016 |
Patient health status and costs in heart failure: insights from the eplerenone post-acute myocardial infarction heart failure efficacy and survival study (EPHESUS).
Topics: Acute Disease; Aged; Cohort Studies; Eplerenone; Female; Follow-Up Studies; Health Care Costs; Healt | 2009 |
Statin therapy and clinical outcomes in myocardial infarction patients complicated by acute heart failure: insights from the EPHESUS trial.
Topics: Acute Disease; Aged; Double-Blind Method; Drug Therapy, Combination; Eplerenone; Female; Heart Failu | 2013 |
[Efficacy of an aldosterone receptor blocker eplerenone in high risk survivors of acute myocardial infarction with signs of heart failure: results of EPHESUS].
Topics: Acute Disease; Diabetes Complications; Drug Administration Schedule; Drug Therapy, Combination; Eple | 2003 |
[Hyperaldosteronism in the acute phase of myocardial infarction. Effects of its treatment on the prevention of ventricular fibrillation].
Topics: Acute Disease; Adult; Aged; Anti-Arrhythmia Agents; Canrenoic Acid; Clinical Trials as Topic; Female | 1984 |
[Clinical evaluation of the use of diuretics in the ascitic phase of hepatic cirrhosis].
Topics: Acute Disease; Adult; Aged; Amiloride; Ascites; Clinical Trials as Topic; Diuretics; Drug Evaluation | 1977 |
Use of spironolactone in the prevention of acute mountain sickness on Kilimanjaro.
Topics: Acute Disease; Adolescent; Adult; Altitude Sickness; Child; Double-Blind Method; Humans; Hypoxia; Mo | 1977 |
Effect of spironolactone on acute mountain sickness.
Topics: Acute Disease; Adult; Double-Blind Method; Humans; Hypoxia; Male; Placebos; Random Allocation; Spiro | 1986 |
27 other studies available for spironolactone and Acute Disease
| Article | Year |
|---|---|
Loeys-Dietz Cardiomyopathy? Long-term Follow-up After Onset of Acute Decompensated Heart Failure.
Topics: Acute Disease; Bisoprolol; Cardiomegaly; Cardiomyopathies; Cardiovascular Agents; Echocardiography; | 2022 |
A rare form of extremely wide QRS complex due to reversed homologous electrical ventricular separation of acute heart failure.
Topics: Acute Disease; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Benzaze | 2018 |
Comparison of effects of aldosterone receptor antagonists spironolactone and eplerenone on cardiovascular outcomes and safety in patients with acute decompensated heart failure.
Topics: Acute Disease; Aged; Eplerenone; Female; Follow-Up Studies; Heart Failure; Humans; Male; Mineralocor | 2019 |
Adding High-Dose Spironolactone to Tolvaptan Improves Acute Decompensated Heart Failure Due to Obstructive Hypertrophic Cardiomyopathy and Aortic Stenosis: A Case Report.
Topics: Acute Disease; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Aortic Valve Stenosis; | 2019 |
Tailoring diuretic therapy in acute heart failure: insight into early diuretic response predictors.
Topics: Acute Disease; Administration, Intravenous; Administration, Oral; Aged; Aged, 80 and over; Diuretics | 2013 |
Use of natriuretic-doses of spironolactone for treatment of loop diuretic resistant acute decompensated heart failure.
Topics: Acute Disease; Aged; Diuretics; Drug Resistance; Female; Heart Failure; Humans; Middle Aged; Mineral | 2014 |
[Mineralocorticoid receptor antagonists as treatment option for acute and chronic central serous chorioretinopathy].
Topics: Acute Disease; Adult; Central Serous Chorioretinopathy; Chronic Disease; Dose-Response Relationship, | 2014 |
Clinical benefit of spironolactone in patients with acute decompensated heart failure and severe renal dysfunction: Data from the Korean Heart Failure Registry.
Topics: Acute Disease; Aged; Aged, 80 and over; Female; Glomerular Filtration Rate; Heart Failure; Hospitali | 2015 |
Importance of biomarkers for long-term mortality prediction in acutely dyspneic patients.
Topics: Acute Disease; Biomarkers; Cohort Studies; Diuretics; Dyspnea; Female; Humans; Interleukin-1 Recepto | 2010 |
Aldosterone blockade in patients with acute myocardial infarction.
Topics: Acute Disease; Catecholamines; Collagen; Eplerenone; Heart Rate; Humans; Mineralocorticoid Receptor | 2003 |
Acute purulent pericarditis in pneumococcal meningitis.
Topics: Acute Disease; Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Female; Humans; Ibuprofen; Menin | 2005 |
Urea transporter UT-A1 and aquaporin-2 proteins decrease in response to angiotensin II or norepinephrine-induced acute hypertension.
Topics: Acute Disease; Aldosterone; Angiotensin II; Animals; Aquaporin 2; Blood Pressure; Drinking; Hyperten | 2006 |
[Effect of spironolactone on mortality in patients with severe left ventricular dysfunction after acute myocardial infarction].
Topics: Acute Disease; Adult; Aged; Cause of Death; Comorbidity; Female; Follow-Up Studies; Heart Failure; H | 2006 |
[Respiratory failure: therapeutic trial on its acute exacerbation].
Topics: Acute Disease; Doxapram; Drug Therapy, Combination; Humans; Respiratory Insufficiency; Spironolacton | 1983 |
Acute myocarditis and left ventricular aneurysm as presentations of systemic lupus erythematosus.
Topics: Acute Disease; Adult; Anti-Inflammatory Agents; Cardiac Output, Low; Diuretics; Endocarditis; Fever; | 1996 |
Allergic contact dermatitis from spironolactone.
Topics: Acne Vulgaris; Acute Disease; Administration, Topical; Adult; Dermatitis, Allergic Contact; Drug Eru | 1996 |
Preventing acute mountain sickness.
Topics: Acute Disease; Altitude Sickness; Diuretics; Humans; Spironolactone | 2001 |
[Management of bronchiolitis in the infant. Recommendations. Long text].
Topics: Acute Disease; Anti-Inflammatory Agents; Antiviral Agents; Bronchiolitis, Viral; Bronchodilator Agen | 2001 |
Prophylaxis of acute mountain sickness.
Topics: Acetazolamide; Acute Disease; Altitude Sickness; Humans; Hypoxia; Mountaineering; Nepal; Spironolact | 1977 |
[Disorder of the mineralocorticoid function of the adrenals in the acute period of myocardial infarct and the ways for its correction].
Topics: Acute Disease; Adrenal Gland Diseases; Adult; Aged; Aldosterone; Chronic Disease; Coronary Disease; | 1979 |
[Control of the depression of gastrointestinal motility in acute pancreatitis using aldosterone antagonists].
Topics: Acute Disease; Gastrointestinal Motility; Humans; Mineralocorticoid Receptor Antagonists; Pancreatit | 1977 |
Spironolactone and acute mountain sickness.
Topics: Acute Disease; Altitude Sickness; Humans; Hypoxia; Mountaineering; Plasma Volume; Spironolactone | 1977 |
Spironolactone and acute mountain sickness.
Topics: Acute Disease; Adult; Altitude Sickness; Aspirin; Female; Furosemide; Humans; Hypoxia; Male; Middle | 1976 |
Spironolactone and acute moutain sickness.
Topics: Acute Disease; Altitude Sickness; Humans; Hypoxia; Mountaineering; Spironolactone | 1976 |
Eosinophilia associated with spironolactone.
Topics: Acute Disease; Aged; Drug Eruptions; Eosinophilia; Humans; Liver Cirrhosis, Alcoholic; Male; Middle | 1986 |
[Aldosteronism in liver diseases].
Topics: Acute Disease; Aldosterone; Chronic Disease; Humans; Hyperaldosteronism; Liver Diseases; Spironolact | 1974 |
[Diuresis and diuretics].
Topics: Acetazolamide; Acute Disease; Agranulocytosis; Anuria; Biological Transport; Blood Platelet Disorder | 1971 |